Advertisement
U.S. markets close in 3 hours
Advertisement

Cumberland Pharmaceuticals Inc. (CPIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
1.8100+0.0200 (+1.12%)
As of 12:49PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
Previous Close1.7900
Open1.7300
Bid1.8100 x 1000
Ask1.8200 x 800
Day's Range1.7300 - 1.8150
52 Week Range1.4300 - 2.9100
Volume2,236
Avg. Volume20,070
Market Cap26.012M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CPIX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cumberland Pharmaceuticals Inc.
    PCRX: Lowering target price to $35.00PACIRA BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $35.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
  • PR Newswire

    Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

    Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023.

  • PR Newswire

    CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

    Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.

  • PR Newswire

    NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS

    Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs1. Caldolor (ibuprofen) injection, is an intravenous non-steroidal anti-inflammatory drug (NSAID) approved by the FDA for the treatment of pain and fever in adults and children. The results of this published study supported